163 related articles for article (PubMed ID: 24534652)
1. Doxorubicin and trastuzumab regimen induces biventricular failure in mice.
Milano G; Raucci A; Scopece A; Daniele R; Guerrini U; Sironi L; Cardinale D; Capogrossi MC; Pompilio G
J Am Soc Echocardiogr; 2014 May; 27(5):568-79. PubMed ID: 24534652
[TBL] [Abstract][Full Text] [Related]
2. The role of renin angiotensin system antagonists in the prevention of doxorubicin and trastuzumab induced cardiotoxicity.
Akolkar G; Bhullar N; Bews H; Shaikh B; Premecz S; Bordun KA; Cheung DY; Goyal V; Sharma AK; Garber P; Singal PK; Jassal DS
Cardiovasc Ultrasound; 2015 Apr; 13():18. PubMed ID: 25889218
[TBL] [Abstract][Full Text] [Related]
3. Congenital absence of nitric oxide synthase 3 potentiates cardiac dysfunction and reduces survival in doxorubicin- and trastuzumab-mediated cardiomyopathy.
Zeglinski M; Premecz S; Lerner J; Wtorek P; Dasilva M; Hasanally D; Chaudhary R; Sharma A; Thliveris J; Ravandi A; Singal PK; Jassal DS
Can J Cardiol; 2014 Mar; 30(3):359-67. PubMed ID: 24484915
[TBL] [Abstract][Full Text] [Related]
4. Overweight in mice, induced by perinatal programming, exacerbates doxorubicin and trastuzumab cardiotoxicity.
Guenancia C; Hachet O; Aboutabl M; Li N; Rigal E; Cottin Y; Rochette L; Vergely C
Cancer Chemother Pharmacol; 2016 Apr; 77(4):777-85. PubMed ID: 26914236
[TBL] [Abstract][Full Text] [Related]
5. The Cardioprotective Role of N-Acetyl Cysteine Amide in the Prevention of Doxorubicin and Trastuzumab-Mediated Cardiac Dysfunction.
Goyal V; Bews H; Cheung D; Premecz S; Mandal S; Shaikh B; Best R; Bhindi R; Chaudhary R; Ravandi A; Thliveris J; Singal PK; Niraula S; Jassal DS
Can J Cardiol; 2016 Dec; 32(12):1513-1519. PubMed ID: 27650929
[TBL] [Abstract][Full Text] [Related]
6. Intravenous administration of cardiac progenitor cell-derived exosomes protects against doxorubicin/trastuzumab-induced cardiac toxicity.
Milano G; Biemmi V; Lazzarini E; Balbi C; Ciullo A; Bolis S; Ameri P; Di Silvestre D; Mauri P; Barile L; Vassalli G
Cardiovasc Res; 2020 Feb; 116(2):383-392. PubMed ID: 31098627
[TBL] [Abstract][Full Text] [Related]
7. The Cardioprotective Role of Flaxseed in the Prevention of Doxorubicin- and Trastuzumab-Mediated Cardiotoxicity in C57BL/6 Mice.
Asselin CY; Lam A; Cheung DYC; Eekhoudt CR; Zhu A; Mittal I; Mayba A; Solati Z; Edel A; Austria JA; Aukema HM; Ravandi A; Thliveris J; Singal PK; Pierce GN; Niraula S; Jassal DS
J Nutr; 2020 Sep; 150(9):2353-2363. PubMed ID: 32510147
[TBL] [Abstract][Full Text] [Related]
8. The cardioprotective role of probucol against anthracycline and trastuzumab-mediated cardiotoxicity.
Walker JR; Sharma A; Lytwyn M; Bohonis S; Thliveris J; Singal PK; Jassal DS
J Am Soc Echocardiogr; 2011 Jun; 24(6):699-705. PubMed ID: 21353471
[TBL] [Abstract][Full Text] [Related]
9. Comparing Flaxseed and Perindopril in the Prevention of Doxorubicin and Trastuzumab-Induced Cardiotoxicity in C57Bl/6 Mice.
Eekhoudt CR; Bortoluzzi T; Varghese SS; Cheung DYC; Christie S; Eastman S; Mittal I; Austria JA; Aukema HM; Ravandi A; Thliveris J; Singal PK; Jassal DS
Curr Oncol; 2022 Apr; 29(5):2941-2953. PubMed ID: 35621631
[TBL] [Abstract][Full Text] [Related]
10. Structural and Electrophysiological Changes in a Model of Cardiotoxicity Induced by Anthracycline Combined With Trastuzumab.
Altomare C; Lodrini AM; Milano G; Biemmi V; Lazzarini E; Bolis S; Pernigoni N; Torre E; Arici M; Ferrandi M; Barile L; Rocchetti M; Vassalli G
Front Physiol; 2021; 12():658790. PubMed ID: 33897465
[TBL] [Abstract][Full Text] [Related]
11. Utility of tissue Doppler and strain rate imaging in the early detection of trastuzumab and anthracycline mediated cardiomyopathy.
Jassal DS; Han SY; Hans C; Sharma A; Fang T; Ahmadie R; Lytwyn M; Walker JR; Bhalla RS; Czarnecki A; Moussa T; Singal PK
J Am Soc Echocardiogr; 2009 Apr; 22(4):418-24. PubMed ID: 19269133
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic Evidence of MSCs-Derived Exosomes in Doxorubicin/Trastuzumab-Induced Cardiotoxicity: Beyond Mechanistic Target of NRG-1/Erb Signaling Pathway.
Ebrahim N; Al Saihati HA; Mostafa O; Hassouna A; Abdulsamea S; Abd El Aziz M El Gebaly E; Abo-Rayah NH; Sabry D; El-Sherbiny M; Madboly AG; Hussien NI; Saadani REH; Ebrahim HA; Badr OAM; Elsherbiny NM; Salim RF
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682646
[TBL] [Abstract][Full Text] [Related]
13. Temporal Trends of Cardiac Chambers Function with Trastuzumab in Human Epidermal Growth Factor Receptor II-Positive Breast Cancer Patients.
Moustafa S; Murphy K; Nelluri BK; Northfelt D; Shah P; Lee H; Wilansky S; Naqvi TZ; Meyer S; Mookadam F
Echocardiography; 2016 Mar; 33(3):406-15. PubMed ID: 26498324
[TBL] [Abstract][Full Text] [Related]
14. Cardiac MRI Myocardial Functional and Tissue Characterization Detects Early Cardiac Dysfunction in a Mouse Model of Chemotherapy-Induced Cardiotoxicity.
Naresh NK; Misener S; Zhang Z; Yang C; Ruh A; Bertolino N; Epstein FH; Collins JD; Markl M; Procissi D; Carr JC; Allen BA
NMR Biomed; 2020 Sep; 33(9):e4327. PubMed ID: 32567177
[TBL] [Abstract][Full Text] [Related]
15. Development of doxorubicin-induced chronic cardiotoxicity in the B6C3F1 mouse model.
Desai VG; Herman EH; Moland CL; Branham WS; Lewis SM; Davis KJ; George NI; Lee T; Kerr S; Fuscoe JC
Toxicol Appl Pharmacol; 2013 Jan; 266(1):109-21. PubMed ID: 23142469
[TBL] [Abstract][Full Text] [Related]
16. Catching broken hearts: pre-clinical detection of doxorubicin and trastuzumab mediated cardiac dysfunction in the breast cancer setting.
Saeed MF; Premecz S; Goyal V; Singal PK; Jassal DS
Can J Physiol Pharmacol; 2014 Jul; 92(7):546-50. PubMed ID: 24959994
[TBL] [Abstract][Full Text] [Related]
17. Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms.
Rochette L; Guenancia C; Gudjoncik A; Hachet O; Zeller M; Cottin Y; Vergely C
Trends Pharmacol Sci; 2015 Jun; 36(6):326-48. PubMed ID: 25895646
[TBL] [Abstract][Full Text] [Related]
18. Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer.
Cochet A; Quilichini G; Dygai-Cochet I; Touzery C; Toubeau M; Berriolo-Riedinger A; Coudert B; Cottin Y; Fumoleau P; Brunotte F
Breast Cancer Res Treat; 2011 Dec; 130(3):845-54. PubMed ID: 21918836
[TBL] [Abstract][Full Text] [Related]
19. Plasmatic and chamber-specific modulation of cardiac microRNAs in an acute model of DOX-induced cardiotoxicity.
Gioffré S; Ricci V; Vavassori C; Ruggeri C; Chiesa M; Alfieri I; Zorzan S; Buzzetti M; Milano G; Scopece A; Castiglioni L; Sironi L; Pompilio G; Colombo GI; D'Alessandra Y
Biomed Pharmacother; 2019 Feb; 110():1-8. PubMed ID: 30453253
[TBL] [Abstract][Full Text] [Related]
20. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy.
Fallah-Rad N; Walker JR; Wassef A; Lytwyn M; Bohonis S; Fang T; Tian G; Kirkpatrick ID; Singal PK; Krahn M; Grenier D; Jassal DS
J Am Coll Cardiol; 2011 May; 57(22):2263-70. PubMed ID: 21616287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
